KTTAW
MaterialsPasithea Therapeutics Corp. Warrants
$0.01
+13.00%
Live · NASDAQ · Mar 28, 6:08 AM
AI InsightNo insight available
What's Moving KTTAW Today?
No AI insight has been generated for KTTAW yet. Check back soon — insights are generated from recent news analysis.
Generated Insights
No insights have been generated for KTTAW yet. Check back soon.
KTTAW News
19 articles- Pasithea Therapeutics Announces Activation of Clinical Trial Site at University of Alabama at Birmingham for Ongoing Phase 1/1b Trial of PAS-004 in Adult NF1 PatientsYahoo Finance·Nov 4, 2025
- Pasithea Therapeutics Announces Activation of Clinical Trial Sites in South Korea for Phase 1/1b Trial of PAS-004 in Adult NF1 PatientsYahoo Finance·Sep 16, 2025
- Pasithea Therapeutics Announces Enrollment of Cohort 2 following Positive Safety Review Committee (SRC) Recommendation for its Ongoing Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 PatientsYahoo Finance·Sep 8, 2025
- Pasithea Therapeutics Updates Time of Presentation at the H.C. Wainwright 27th Annual Global Investment ConferenceYahoo Finance·Aug 29, 2025
- Pasithea Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment ConferenceYahoo Finance·Aug 28, 2025
- Pasithea Therapeutics Completes Enrollment and Initial Dosing of First Cohort from its Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 PatientsYahoo Finance·Jul 31, 2025
- Pasithea Therapeutics Appoints Expert in ETS2-driven Inflammatory Disease to Scientific Advisory BoardYahoo Finance·Jun 11, 2025
- Pasithea Therapeutics Presents Updated Interim Data from Ongoing Phase 1 Study of PAS-004 at the ASCO Annual Meeting 2025Yahoo Finance·Jun 2, 2025
- Pasithea Therapeutics Announces Preclinical Data that Shows PAS-004 Inhibits ETS2 Signaling, a Key Driver of Inflammation in IBD and Other Large Addressable Market DiseasesYahoo Finance·May 20, 2025
- Pasithea to commence Phase I/Ib trial of neurofibromatosis type 1 therapyClinicaltrialsarena·May 15, 2025
- Pasithea Therapeutics Announces Initiation of Phase 1/1B Study of PAS-004 in Adult NF1 Patients and Activation of First Clinical Trial SiteYahoo Finance·May 14, 2025
- Pasithea Therapeutics Announces Closing of $5 Million Public OfferingYahoo Finance·May 7, 2025
- Pasithea Therapeutics 3.57M share Secondary priced at $1.40Yahoo Finance·May 7, 2025
- Pasithea Therapeutics Announces Pricing of $5 Million Public OfferingYahoo Finance·May 6, 2025
- Pasithea Therapeutics Reports Positive Pharmacodynamic Results Demonstrating Robust Target Engagement from its Ongoing Phase 1 Clinical Trial of PAS-004Yahoo Finance·May 6, 2025
- Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Patients in Cohort 6 from its Phase 1 Trial of PAS-004 in Advanced Cancer PatientsYahoo Finance·Apr 29, 2025
- Pasithea Therapeutics to Present Updated Data from Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients at the 2025 ASCO Annual MeetingYahoo Finance·Apr 24, 2025
- Sector Update: Health Care Stocks Drop Thursday AfternoonYahoo Finance·Apr 10, 2025
- Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its Ongoing Phase 1 Clinical Trial of PAS-004 in Advanced CancerYahoo Finance·Apr 10, 2025
All 19 articles loaded
Price Data
Open$0.00
Previous Close$0.01
Day High$0.00
Day Low$0.00
52 Week High$0.12
52 Week Low$0.01
52-Week Range
$0.01$0.12
$0.01
Fundamentals
Market Cap—
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE-94.1%
Profit Margin—
Debt / Equity0.09
Trading
Volume—
Avg Volume (10D)43K
Shares Outstanding—
About Pasithea Therapeutics Corp. Warrants
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module).
1111 LINCOLN ROAD, SUITE 500, MIAMI BEACH, FL, 33139
4 employees
Listed September 15, 2021
MaterialsPHARMACEUTICAL PREPARATIONS
Company Details
Security TypeWarrant
ExchangeNASDAQ
CurrencyUSD
Round Lot100
SIC2834 — PHARMACEUTICAL PREPARATIONS
CIK0001841330
Composite FIGIBBG01231TZF3
Share Class FIGI—